(Q43739781)

26 November 2017

title

Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program (English)

1 reference

26 November 2017

Taylor AJ

1

1 reference

26 November 2017

Grace K

2

1 reference

26 November 2017

Swiecki J

3

1 reference

26 November 2017

Hyatt R

4

1 reference

26 November 2017

Gibbs H

5

1 reference

26 November 2017

Sheikh M

6

1 reference

26 November 2017

O'Malley PG

7

1 reference

26 November 2017

Lowenthal SP

8

1 reference

26 November 2017

West M

9

1 reference

26 November 2017

Spain J

10

1 reference

26 November 2017

Maneval K

11

1 reference

26 November 2017

Jones DL

12

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

21

1 reference

26 November 2017

issue

9

1 reference

26 November 2017

page(s)

1130-1139

1 reference

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

Clinical pharmacokinetics of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.21.13.1130.34616

10.1592/PHCO.21.13.1130.34616

21 January 2018

Identifiers

DOI

1 reference

26 November 2017

1 reference